Filing Flows

Filing Flows › Companies › Entrada Therapeutics › Cash flow

Entrada Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$30.1M in Q3 2026 · −$136M over twelve months

Operating cash flow−$30.0M
Capital spending−$161K
Free cash flow−$30.1M

Analysis

In Q3 2026, Entrada Therapeutics generated −$30.0M of operating cash flow and spent $161K on capital projects, leaving free cash flow of −$30.1M. That is $2.0M less than in Q3 2025 (−$28.1M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$136M; the largest uses were operating cash flow ($136M), capital spending ($9K); besides operations, cash came from other investing ($154M), other financing ($465K); the cash balance rose by $18.3M.

Operating cash flow was −$30.0M against net income of −$39.7M. The largest differences: stock-based pay +$4.8M, accrued liabilities +$3.3M, payables +$1.1M.

Free cash flow

Entrada Therapeutics: free cash flow by quarterEntrada Therapeutics: free cash flow by quarter−$32.2MQ4 2024−$39.7MQ1 2025−$29.8MQ2 2025−$28.1MQ3 2025−$32.0MQ4 2025−$41.7MQ1 2026−$32.5MQ2 2026−$30.1MQ3 2026
Operating cash flow less capital spending.
Entrada Therapeutics: operating cash flow against capital spendingEntrada Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$31.6M$635KQ4 2024−$38.5M$1.1MQ1 2025−$29.5M$275KQ2 2025−$28.3M−$171KQ3 2025−$32.2M−$207KQ4 2025−$41.7M$44KQ1 2026−$32.5M$11KQ2 2026−$30.0M$161KQ3 2026
Latest (Q3 2026): Operating cash flow −$30.0M, Capital spending $161K.

Capital allocation, year by year

Entrada Therapeutics: where the cash came from (up) and went (down), by fiscal yearEntrada Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$50.9MFY2021: Shares issued $191MFY2021: Capital spending −$4.6M$191MFY2021FY2022: Operating cash flow −$93.8MFY2022: Shares issued $479KFY2022: Capital spending −$2.9M$479KFY2022FY2023: Operating cash flow $140MFY2023: Shares issued $1.6MFY2023: Capital spending −$5.6M$141MFY2023FY2024: Operating cash flow −$41.6MFY2024: Shares issued $5.6MFY2024: Capital spending −$3.2M$5.6MFY2024FY2025: Operating cash flow −$129MFY2025: Shares issued $425KFY2025: Capital spending −$1.0M$425KFY2025
Over these 5 years operating cash flow totalled −$175M; the largest uses were operating cash flow ($315M) and capital spending ($17.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$112M
Debtnone
Net cash$112M
Cash runway10 months

Entrada Therapeutics is burning cash: its operations consume cash, a free cash flow of −$136M a year at the current rate against $112M of cash and investments: a runway of about 10 months before any new financing.

Where the cash came from and went

Entrada Therapeutics: sources (+) and uses (−) of cash, Q3 2026Entrada Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other investing$43.1MOperating cash flow−$30.0MCash drawn (+) / kept (−)−$13.0MCapital spending−$161K
Entrada Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Entrada Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing$154MOperating cash flow−$136MCash drawn (+) / kept (−)−$18.3MOther financing$465KShares issued$177KCapital spending−$9K

From profit to cash

Entrada Therapeutics: net income to operating cash flow, Q3 2026Entrada Therapeutics: net income to operating cash flow, Q3 2026Net income−$39.7MDepreciation & amortization$700KStock-based pay$4.8MPayables$1.1MAccrued liabilities$3.3MDeferred revenue−$75KPrepaid and other assets−$218KOperating cash flow−$30.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$30.0M−$161K—−$13.0M−$30.1M
Q2 2026−$32.5M−$11K$30K−$22.8M−$32.5M
Q1 2026−$41.7M−$44K$100K$14.6M−$41.7M
Q4 2025−$32.2M$207K$47K$2.9M−$32.0M
Q3 2025−$28.3M$171K$8K−$20.8M−$28.1M
Q2 2025−$29.5M−$275K$20K−$4.6M−$29.8M
Q1 2025−$38.5M−$1.1M$350K$33.4M−$39.7M
Q4 2024−$31.6M−$635K$1.1M−$23.2M−$32.2M

Entrada Therapeutics: income statement and cash flow

Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year). The chart follows the revenue to costs, profit and cash.

Entrada Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.